What protein is the target of pembrolizumab's binding?

Pembrolizumab is a monoclonal antibody that targets programmed cell‑death protein 1 (PD‑1, also known as PDCD1) on the surface of T cells. By binding PD‑1, it prevents the inhibitory signals that would otherwise dampen the immune response against tumor cells.